Skip Navigation

COVID-19 Update

Retina Research

Retina Research includes retina division faculty-led projects and multiple laboratories engaged in groundbreaking discoveries aimed at transforming the study and treatment of retinal diseases.

  • J. Fernando Arevalo, M.D.
    • Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy
    • Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy
    • Intravitreal Bevacizumab for Diabetic Macular Edema: 5-year Results
    • Intravitreal Bevacizumab for Exudative Age-related Macular Degeneration: 5-year Results
    • Retinal Complications after Anterior versus Posterior Chamber Phakic Intraocular Lens Implantation in Myopia
    • Retinal Detachment in Down Syndrome: Characteristics and Surgical Outcomes
    • Surgical Outcomes of Pars Plana Vitrectomy in the Management of Chronic Traumatic Macular Hole
    • Clinical Characteristics and Treatment of Panuveitis
    • Retinal Detachment in Uveitis
  • Susan Bressler, M.D.
    • All active protocols for the DRCR.net (Diabetes Clinical Research Network) including:
      • Comparison of ranibizumab + prompt or deferred laser vs triamcinolone + prompt laser vs focal/drid laser in the management of diabetic macular edema
      • Assessment of the reproducibility of multiple different spectral domain OCT instruments and comparison to time domain OCT among individuals with diabetes
      • Comparison of ranibizumab/bevacizumab/aflibercept in the management of diabetic macular edema
      • Evaluation of observation vs laser vs anti-VEGF therapy for eyes with diabetic macular edema and good vision
  • Peter Campochairo, M.D.
  • Elia Duh, M.D.
    • Drug delivery with nanomedicine - directing medicine directly to the retina that can last for up to six month
    • Identifying mechanisms on how diabetic retinopathy and AMD progress and the molecules that might cause progression
    • Identifying protective factors against retinal disease so that the protective factors can be enhanced
  • Malia Edwards, Ph.D.
  • Daniel Finkelstein, M.D.
    • The Ethics of the Doctor-Patient Relationship: Using questionnaires and video recording to understand ways to encourage that relationship in order to foster “healing” and compliance.
  • Morton Goldberg, M.D.
    • Incontinentia pigmenti: Dr. Goldberg is re-evaluating patients he initially studied up to two decades ago in order to determine the natural course and proper treatment of this often severe disease, which is inherited only in females and can cause severe retinal (and cerebral) shutdown and overgrowth of arteries and veins, including major hemorrhages in the eye and brain.
  • James Handa, M.D.
    • Studying how oxidized stress magnifies immune response and how the retina protects itself
    • How oxidized lipids damage the retina
    • Designing cell therapy to treat myopia
    • Creating new drugs to treat Stargardt's disease
    • Using robotic surgery to improve retina surgery and to improve surgery education
  • Gerard A. Lutty, Ph.D.
  • Adrianne Scott, M.D.
    • Epidemiology on health disparities in eye care
    • Sickle cell anemia
    • Age-related macular degeneration
    • Retinal vein occlusion
  • Akrit Sodhi, M.D., Ph.D.
    • The role of HIF (hypoxic-inducible factor) regulation and dysregulation in ocular disease, with the goal of identifying novel therapeutic approaches for treatment of a variety of vision-threatening diseases:
      • Identification of a novel “bad” HIF target gene that promotes macular edema
      • Examination of the role of “good” HIF target genes in protecting the retina in dry AMD
      • Using HIF target genes to target and destroy pathological blood vessels in ocular neovascular disease.
  • Sharon D. Solomon, M.D.

    Dr. Solomon’s research is aimed at better understanding the pathophysiology of how idiopathic macular holes develop and to potentially develop targeted non-surgical therapy for this blinding condition. The current treatment for idiopathic macular holes, which occur more commonly in women, involves surgery very often with prolonged face-down positioning. While successful, surgery can be associated with significant complications such as cataract formation, increased eye pressure, retinal tears, and retinal detachment.

    Because a gas bubble is placed in the eye during surgery to close the macular hole, patients have decreased vision for days after surgery and lose time from work because of the need for prolonged face-down positioning.

    Dr. Solomon’s work is implementing proteomics analyses to understand the pathogenesis of macular hole formation. If successful, this research may elucidate the pathophysiology of other surgical retinal diseases, such as vitreomacular traction, lamellar holes, and epiretinal membranes, all of which can cause decreased reading vision that requires surgical intervention.

    Dr. Solomon's initial research on macular holes has gained national attention and is being undertaken in a clinical trial that will involve medical centers across the country.

  • Donald J. Zack, Ph.D.
back to top button